Search company, investor...

Luminous Medical

luminousmedical.com

Total Raised

$32.5M

Investors Count

6

Deal Terms

2

Funding, Valuation & Revenue

3 Fundings

Luminous Medical'slatest funding roundwas aSeries B for $23.5MonMarch 17, 2008.

Luminous Medical'svaluationinNovember 2005was$22.59M.

Luminous Medical's latestpost-money valuationis fromMarch 2008.

Sign up for a free trialto see Luminous Medical's valuations in March 2008 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

3/17/2008

Series B

$23.5M

$99M

0

FY undefined

11/24/2005

Series A

$99M

$22.59M

0

FY undefined

0

Other Investors

0

FY undefined

0

Date

3/17/2008

11/24/2005

Round

Series B

Series A

Other Investors

Amount

$23.5M

$99M

Investors

Valuation

$99M

$22.59M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

Luminous MedicalDeal Terms

2 Deal Terms

Luminous Medical'sdeal structure is available for2fundingrounds, including theirSeries BfromMarch 17, 2008.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

清算價格

Participation

$99M

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

清算價格

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Luminous Medical Investors

6 Investors

Luminous Medical has6 investors.De Novo Venturesinvested in Luminous Medical'sSeries B funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/24/2005

3/17/2008

2
Series A, Series B (2008)

F. Watkins

Venture Capital

California

00/00/0000

00/00/0000

Latterell Venture Partners

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

RiverVest Venture Partners

Subscribe to see more

Venture Capital

Missouri

00/00/0000

00/00/0000

Adams Street Partners

Subscribe to see more

Private Equity

Illinois

00/00/0000

00/00/0000

Finistere Ventures

Subscribe to see more

Venture Capital

California

First funding

11/24/2005

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

3/17/2008

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Latterell Venture Partners

RiverVest Venture Partners

Adams Street Partners

Finistere Ventures

Rounds

2
Series A, Series B (2008)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

F. Watkins

Type

Venture Capital

Venture Capital

Venture Capital

Private Equity

Venture Capital

Location

California

California

Missouri

Illinois

California

Compare Luminous Medical to Competitors

A
ArKal Medical

Arkal Medical is developing a continuous blood glucose sensor for diabetes.

Bay Area Digital Logo
Bay Area Digital

Bay Area Digital is a company that received a SBIR Phase I grant for a project entitled: Talking Blood Glucose Meter with full Accessibility for Blind, Visually and Cognitively Impaired. Their Project addresses a crisis in the lack of effective glucose monitoring equipment for visually and cognitively impaired diabetics. The proposal thoroughly examines the technical and commercial feasibility of developing innovative technology that enables such patients to reliably use information provided by a state-of-the-art blood glucose meter, using speech output that is coupled with a commercially developed meter. There are currently no state-of-the-art or best-of-breed blood glucose meter systems available in the U.S. market with speech capabilities for use by the cognitively, visually impaired or blind community. The development of such a meter will positively impact the self-management of diabetes mellitus, improving quality of life and clinical outcomes for patients and preventing the development of secondary complications and provide an opportunity to impact a major health problem affecting millions of U.S. citizens.

V
Vytrace

Vytrace公司正在開發一個新的重要的care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.

N
Novoculi

Located in Hanover, NH and San Francisco, CA, Novoculi is a medical device company focused on developing a non-invasive, optical blood glucose monitor. Novoculi's Noninvasive Blood Glucose Monitor aims to build on physiologically demonstrated optical phenomena which forms the basis for Novoculi's technology. Novoculi hopes to leverage its technology to develop a non-invasive blood glucose monitor which will allow its patient population to better manage their blood glucose without a painful finger stick.

A
Advanced BioSensors

Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.

G
Glucose Sensing Technologies

Vytrace Corporation (fka Glucose Sensing Technologies) is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions withour sites and services. Use of these cookies, which may be stored on your device,permits us to improve and customize your experience. You can read more about yourcookie choices at our privacy policyhere. By continuing to use thissite you are consenting to these choices.

Baidu
map